OncoCyte Debt to Equity Ratio 2014-2024 | OCX
Current and historical debt to equity ratio values for OncoCyte (OCX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. OncoCyte debt/equity for the three months ending September 30, 2024 was 0.00.
| OncoCyte Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.06B | $0.01B | 6.23 |
| 2024-06-30 | $0.05B | $0.02B | 2.29 |
| 2024-03-31 | $0.06B | $0.01B | 5.13 |
| 2023-12-31 | $0.05B | $0.02B | 2.66 |
| 2023-09-30 | $0.04B | $0.04B | 1.17 |
| 2023-06-30 | $0.04B | $0.04B | 1.01 |
| 2023-03-31 | $0.05B | $0.04B | 1.18 |
| 2022-12-31 | $0.07B | $0.03B | 1.92 |
| 2022-09-30 | $0.08B | $0.08B | 1.05 |
| 2022-06-30 | $0.09B | $0.08B | 1.06 |
| 2022-03-31 | $0.09B | $0.06B | 1.57 |
| 2021-12-31 | $0.09B | $0.07B | 1.45 |
| 2021-09-30 | $0.07B | $0.10B | 0.69 |
| 2021-06-30 | $0.08B | $0.10B | 0.73 |
| 2021-03-31 | $0.02B | $0.11B | 0.21 |
| 2020-12-31 | $0.02B | $0.03B | 0.66 |
| 2020-09-30 | $0.02B | $0.04B | 0.67 |
| 2020-06-30 | $0.02B | $0.04B | 0.60 |
| 2020-03-31 | $0.02B | $0.04B | 0.63 |
| 2019-12-31 | $0.01B | $0.03B | 0.29 |
| 2019-09-30 | $0.00B | $0.03B | 0.12 |
| 2019-06-30 | $0.00B | $0.03B | 0.12 |
| 2019-03-31 | $0.00B | $0.04B | 0.09 |
| 2018-12-31 | $0.01B | $0.00B | 1.78 |
| 2018-09-30 | $0.01B | $0.01B | 0.72 |
| 2018-06-30 | $0.01B | $0.01B | 0.78 |
| 2018-03-31 | $0.01B | $0.01B | 0.73 |
| 2017-12-31 | $0.01B | $0.00B | 1.32 |
| 2017-09-30 | $0.01B | $0.01B | 0.77 |
| 2017-06-30 | $0.01B | $0.01B | 1.15 |
| 2017-03-31 | $0.01B | $0.01B | 0.73 |
| 2016-12-31 | $0.01B | $0.01B | 0.47 |
| 2016-09-30 | $0.00B | $0.01B | 0.33 |
| 2016-06-30 | $0.00B | $0.00B | 0.66 |
| 2016-03-31 | $0.00B | $0.01B | 0.40 |
| 2015-12-31 | $0.00B | $0.01B | 0.22 |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2015-03-31 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.01B | $-0.00B | -5.90 |
| 2013-12-31 | $0.01B | $0.00B | 1.29 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.043B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $91.424B | 11.34 |
| Cencora (COR) | United States | $47.484B | 17.51 |
| DiDi Global (DIDIY) | China | $23.330B | 0.00 |
| Natera (NTRA) | United States | $21.401B | 0.00 |
| ICON (ICLR) | Ireland | $16.136B | 14.37 |
| Viatris (VTRS) | United States | $15.576B | 4.80 |
| Avantor (AVTR) | United States | $13.422B | 20.12 |
| Revvity (RVTY) | United States | $13.376B | 23.24 |
| CochLear (CHEOY) | Australia | $12.844B | 0.00 |
| BioMerieux (BMXMF) | France | $12.666B | 0.00 |
| Solventum (SOLV) | United States | $11.583B | 0.00 |
| Medpace Holdings (MEDP) | United States | $9.789B | 27.58 |
| Doximity (DOCS) | United States | $9.620B | 56.63 |
| Charles River Laboratories (CRL) | United States | $9.516B | 18.39 |
| HealthEquity (HQY) | United States | $8.966B | 48.66 |
| Sonic Healthcare (SKHHY) | Australia | $8.758B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.885B | 32.05 |
| Life Times (LTH) | United States | $5.085B | 33.66 |
| Sotera Health (SHC) | United States | $3.855B | 20.62 |
| Organon (OGN) | United States | $3.757B | 3.79 |
| BrightSpring Health Services (BTSG) | United States | $3.247B | 69.07 |
| Surgery Partners (SGRY) | United States | $2.892B | 32.97 |
| PACS (PACS) | United States | $2.606B | 0.00 |
| Concentras Parent (CON) | United States | $2.581B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.375B | 0.00 |
| Premier (PINC) | United States | $2.143B | 11.15 |
| Alignment Healthcare (ALHC) | United States | $2.126B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.952B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.616B | 42.40 |
| Teladoc Health (TDOC) | United States | $1.537B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.255B | 12.28 |
| CareDx (CDNA) | United States | $1.183B | 0.00 |
| Progyny (PGNY) | United States | $1.164B | 23.57 |
| Establishment Labs Holdings (ESTA) | $1.050B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.954B | 6.46 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Embecta (EMBC) | United States | $0.778B | 5.18 |
| SBC Medicals (SBC) | United States | $0.677B | 0.00 |
| Agilon Health (AGL) | United States | $0.655B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.647B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.536B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.425B | 0.00 |
| DocGo (DCGO) | United States | $0.410B | 15.46 |
| Enhabit (EHAB) | United States | $0.366B | 31.61 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.326B | 0.00 |
| LifeMD (LFMD) | United States | $0.241B | 0.00 |
| ModivCare (MODV) | United States | $0.223B | 12.09 |
| Sera Prognostics (SERA) | United States | $0.209B | 0.00 |
| Beauty Health (SKIN) | United States | $0.200B | 0.00 |
| Biodesix (BDSX) | United States | $0.180B | 0.00 |
| Nutex Health (NUTX) | United States | $0.156B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.100B | 0.00 |
| So-Young (SY) | China | $0.092B | 22.25 |
| MultiPlan (MPLN) | United States | $0.084B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.054B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.08 |
| Co-Diagnostics (CODX) | United States | $0.034B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.030B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.028B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.020B | 0.00 |
| Oncology Institute (TOI) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |